Javier Salmeron
Overview
Explore the profile of Javier Salmeron including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
1598
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roa-Colomo A, Lopez Garrido M, Molina-Vallejo P, Rojas A, Sanchez M, Aranda-Garcia V, et al.
Front Mol Biosci
. 2022 Dec;
9:1074277.
PMID: 36518850
Lack of diagnostic and prognostic biomarkers in hepatocellular carcinoma impedes stratifying patients based on their risk of developing cancer. The aim of this study was to evaluate phenotypic and genetic...
2.
Lopez-Perez D, Redruello-Romero A, Garcia-Rubio J, Arana C, Garcia-Escudero L, Tamayo F, et al.
Front Endocrinol (Lausanne)
. 2022 Apr;
13:818388.
PMID: 35370964
The paradigm of mast cells in type 2 diabetes is changing. Although they were first considered deleterious inflammatory cells, now they seem to be important players driving adipose tissue homeostasis....
3.
Lopez-Perez D, Redruello-Romero A, Garcia-Rubio J, Arana C, Garcia-Escudero L, Tamayo F, et al.
Front Immunol
. 2021 Jun;
12:664576.
PMID: 34093556
Type 2 diabetes (T2D) is a rising global health problem mainly caused by obesity and a sedentary lifestyle. In healthy individuals, white adipose tissue (WAT) has a relevant homeostatic role...
4.
Ampuero J, Aller R, Gallego-Duran R, Crespo J, Abad J, Gonzalez-Rodriguez A, et al.
Liver Int
. 2021 Apr;
41(9):2076-2086.
PMID: 33896100
Background And Aim: Histological score systems may not fully capture the essential nonalcoholic steatohepatitis (NASH) features, which is one of the leading causes of screening failure in clinical trials. We...
5.
Ampuero J, Aller R, Gallego-Duran R, Crespo J, Calleja J, Garcia-Monzon C, et al.
J Hepatol
. 2020 Jul;
73(3):740-741.
PMID: 32654856
No abstract available.
6.
Ruiz-Extremera A, Diaz-Alcazar M, Munoz-Gamez J, Cabrera-Lafuente M, Martin E, Arias-Llorente R, et al.
PLoS One
. 2020 May;
15(5):e0233528.
PMID: 32437468
Background & Aim: Worldwide, measures are being implemented to eradicate hepatitis B (HBV) and C (HCV) viruses, which can be transmitted from the mother during childbirth. This study aims to...
7.
Ampuero J, Aller R, Gallego-Duran R, Crespo J, Calleja J, Garcia-Monzon C, et al.
J Hepatol
. 2020 Mar;
73(1):17-25.
PMID: 32147361
Background & Aims: Non-alcoholic fatty liver disease (NAFLD) could play a catalytic role in the development of metabolic comorbidities, although the magnitude of this effect in metabolically healthy patients with...
8.
Chen Q, Perales C, Soria M, Garcia-Cehic D, Gregori J, Rodriguez-Frias F, et al.
Antiviral Res
. 2019 Dec;
174:104694.
PMID: 31857134
A percentage of hepatitis C virus (HCV)-infected patients fail direct acting antiviral (DAA)-based treatment regimens, often because of drug resistance-associated substitutions (RAS). The aim of this study was to characterize...
9.
Bataller R, Cabezas J, Aller R, Ventura-Cots M, Abad J, Albillos A, et al.
Gastroenterol Hepatol
. 2019 Nov;
42(10):657-676.
PMID: 31771785
Alcohol-related liver disease (ARLD) is the most prevalent cause of advanced liver disease and liver cirrhosis in Europe, including Spain. According to the World Health Organization the fraction of liver...
10.
Sousa J, Vergara M, Pulido F, Antolin G, Hijona L, Carnicer F, et al.
PLoS One
. 2019 Nov;
14(11):e0225061.
PMID: 31714950
Aim: We describe the effectiveness and safety of the interferon-free regimen ombitasvir/paritaprevir/ritonavir plus dasabuvir with or without ribavirin (OBV/PTV/r ± DSV ± RBV) in a nationwide representative sample of the...